EGFR over-expression, correlation between EGFR-HER3 axis activation and poor outcome, and higher levels of cytoplasmic Src in TNBC compared to other breast cancer subtypes also point to potential therapeutic value for a pan-HER inhibitor and Src inhibitor in TNBC [[41], [42], [43]]. This evidence concerns the gene ERBB3 and breast carcinoma.